Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 45.96% | 35.65% | 60.20% | 79.39% | 58.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.03% | 37.41% | 59.14% | 62.19% | 52.52% |
| Operating Income | 3.03% | -37.41% | -59.14% | -62.19% | -52.52% |
| Income Before Tax | 11.02% | -7.85% | -6.81% | -45.88% | -42.17% |
| Income Tax Expenses | -95.05% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.12% | -7.98% | -6.95% | -46.07% | -42.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -67.53% | 4.70% | 43.96% | 52.57% | 44.17% |
| Net Income | 9.63% | -8.05% | -6.21% | -45.91% | -42.30% |
| EBIT | 3.03% | -37.41% | -59.14% | -62.19% | -52.52% |
| EBITDA | -23.58% | -37.50% | -59.83% | -62.63% | -52.87% |
| EPS Basic | 16.02% | 21.26% | 19.91% | -21.40% | -15.39% |
| Normalized Basic EPS | 34.38% | 21.37% | 20.39% | -21.24% | -15.28% |
| EPS Diluted | 15.34% | 21.26% | 19.91% | -21.40% | -15.39% |
| Normalized Diluted EPS | 34.38% | 21.37% | 20.39% | -21.24% | -15.28% |
| Average Basic Shares Outstanding | 40.55% | 40.32% | 35.36% | 22.63% | 25.28% |
| Average Diluted Shares Outstanding | 40.55% | 40.32% | 35.36% | 22.63% | 25.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
